연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
2221. The U-shaped association between body mass index and gastric cancer risk in the Helicobacter pylori Biomarker Cohort Consortium: A nested case-control study from eight East Asian cohort studies.
Jang J, Wang T, Cai H, Ye F, Murphy G, Shimazu T, Taylor PR, Qiao YL, Yoo KY, Jee SH, Kim J, Chen SC, Abnet CC, Tsugane S, Zheng W, Shu XO, Pawlita M, Park SK, Epplein M.
Int J Cancer. 2019 Nov 19. doi: 10.1002/ijc.32790.
[Epub ahead of print]
Link
2220. Cancer cell-induced neutrophil extracellular traps promote both hypercoagulability and cancer progression.
Jung HS1,2, Gu J1,2, Kim JE3, Nam Y1, Song JW4, Kim HK1,2.
PLoS One. 2019 Apr 29;14(4):e0216055. doi: 10.1371/journal.pone.0216055. eCollection 2019.
Link
2219. Thrombotic Risk of Non-Criteria Anti-Phospholipid Antibodies Measured by Line Immunoassay: Superiority of Anti-Phosphatidylserine and Anti-Phosphatidic Acid Antibodies.
Park HS, Gu JY, Jung HS, Kim HK.
Clin Lab. 2019 Mar 1;65(3). doi: 10.7754/Clin.Lab.2018.171207.
Link
2218. Contact System Activation and Neutrophil Extracellular Trap Markers: Risk Factors for Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma.
Seo JD1, Gu JY1, Jung HS1, Kim YJ2, Kim HK1.
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029618825310. doi: 10.1177/1076029618825310.
Link
2217. Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age.
Seo YS, Kim HJ, Wu HG, Choi SM, Park S
Thorac Cancer. 2019 Jun;10(6):1489-1499
Link
2216. Identification of FES as a Novel Radiosensitizing Target in Human Cancers.
Kim BH, Kim YJ, Kim MH, Na YR, Jung D, Seok SH, Kim J, Kim HJ.
Clin Cancer Res. 2019 Oct 1
Link
2215. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL1,2, Kim HP1,2, Cho YW1,2, Min DW1,2, Cheon SK1,2, Lim YJ3, Song SH2, Kim SJ4, Han SW2,3, Park KJ5, Kim TY1,2,3.
Int J Cancer. 2019 Jan 15;144(2):389-401. doi: 10.1002/ijc.31662. Epub 2018 Nov 29.
Link
2214. Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
Lee Y1, Kim TM2, Kim DW3, Kim S4, Kim M3, Keam B3, Ku JL1, Heo DS3.
J Thorac Oncol. 2019 Sep;14(9):1556-1566. doi: 10.1016/j.jtho.2019.05.006. Epub 2019 May 17.
Link
2213. NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.
Park HR1, Ahn YO2, Kim TM3, Kim S4, Kim S1, Lee YS1, Kim M5, Keam B5, Kim DW5, Heo DS5.
Cytotherapy. 2019 Jun;21(6):603-611. doi: 10.1016/j.jcyt.2019.03.312. Epub 2019 Apr 20.
Link
2212. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma.
Kim WJ1, Dho YS1, Ock CY2, Kim JW1, Choi SH3, Lee ST4, Kim IH5, Kim TM6, Park CK7.
J Neurooncol. 2019 Jun;143(2):321-328. doi: 10.1007/s11060-019-03167-2. Epub 2019 Apr 13.
Link